Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension

Hypertension Research

Volumn 32, Issue 3, 2009, Pages 169-175

  Kushiro, Toshio ^a   Itakura, Hiroshige ^b   Abo, Yoshihisa ^c   Gotou, Hiromi ^d   Terao, Shinji ^d   Keefe, Deborah L ^e  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Shinagawa East One Medical Clinic   (Japan)

^c Department of Internal Medicine   (Japan)

^d NOVARTIS PHARMA K K   (Japan)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; AMLODIPINE; INDAPAMIDE; TRICHLORMETHINE;

ADD ON THERAPY; ADULT; AGED; ALLERGY; ARTICLE; BACKACHE; BLOOD PRESSURE REGULATION; BODY MASS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INFECTION; INFESTATION; JAPANESE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OPEN STUDY; PHARYNGITIS; POTASSIUM BLOOD LEVEL; PULSE RATE; RHINOPHARYNGITIS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; WEIGHT CHANGE;

ADULT; AGED; AGED, 80 AND OVER; AMIDES; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; FUMARATES; HEART RATE; HUMANS; HYPERTENSION; JAPAN; LONG-TERM CARE; MALE; MIDDLE AGED; RENIN; YOUNG ADULT;

EID: 68249144573     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2008.21     Document Type: Article

References (24)

1. Japanese Society of Hypertension. Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). Hypertens Res 2006; 29: S1-S106.
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, Jones DW, Materson BJ, Oparil S, Wright Jr JT, Roccella EJ, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee\par. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003; 289: 2560-2572.
3. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension [Guidelines]. J Hypertens 2007; 25: 1751-1762.
4. Fujita T, Wu Z, Park JB, Chen MF. Briefings on JHS, CHS, KHS and THS guidelines and their difference from JNC VII and ESC/ESH. Int J Clin Pract 2006; 60: 3-6.
5. Neutel JM, Smith DH. Improving patient compliance: A major goal in the management of hypertension. J Clin Hypertens 2003; 5: 127-132.
6. Krousel-Wood M, Thomas S, Muntner P, Morisky D. Medication adherence: A key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol 2004; 19 357-362.
7. Tassell BW, Munger MA. Aliskiren for renin inhibition: A new class of antihypertensives. Ann Pharmacother 2007; 41: 456-464.
8. Azizi M. Renin inhibition: The next step in suppression of the renin-angiotensin system? Curr Hypertens Rep 2007; 9: 81-83.
9. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomised, double-blind trial. Lancet 2007; 370: 221-229.
10. Andersen K, Weinberger MH, Egan B, Constance CM, Ali MA, Jin J, Keefe DL. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: A 6-month, randomized, double-blind trial. J Hypertens 2008; 26: 589-599.
11. Drummond W, Munger MA, Rafique Essop M, Maboudian M, Khan M, Keefe DL. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens (Greenwich) 2007; 9: 742-750.
12. Villamil A, Chrysant SG, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L, Zhang J. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Hypertension 2007; 25: 217-226.
13. Kushiro T, Itakura H, Abo Y, Gotou H, Terao S, Keefe DL. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res 2006; 29: 997-1005.
14. Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007; 49: 1157-1163.
15. Sica D, Gradman AH, Lederballe O, Meyers M, Cai J, Keefe DL. Aliskiren, a novel renin inhibitor, is well tolerated and has sustained BP-lowering effects alone or in combination with HCTZ during long-term (52 weeks) treatment of hypertension [abstract]. Eur Heart J 2006; 27: P797.
16. Vaidyanathan S, Jermany J, Yeh C, Bizot MN, Camisasca R. Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. Br J Clin Pharmacol 2006; 62: 690-698.
17. Black HR, Elliott WJ, Neaton JD, Grandits G, Grambsch P, Grimm Jr RH, Hansson L, Lacoucière Y, Muller J, Sleight P, Weber MA, White WB, Williams G, Wittes J, Zanchetti A, Fakouhi TD, Anders RJ. Baseline characteristics and early blood pressure control in the CONVINCE trial. Hypertension 2001; 37: 12-18.
18. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright Jr JT, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM, ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002; 4: 393-404.
19. Uresin Y, Taylor A, Kilo C, Tschope D, Santonastaso M, Ibram G, Fang H, Satlin A. Aliskiren, a novel renin inhibitor, has greater BP lowering than ramipril and additional BP lowering when combined with ramipril in patients with diabetes and hypertension [Abstract]. J Hypertens 2006; 24: S82.
20. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 111: 1012-1018.
21. Stanton A. Therapeutic potential of renin inhibitors in the management of cardiovascular disorders. Am J Cardiovasc Drug 2003; 3: 389-394.
22. Weir MR, Bush C, Zhang J, Keefe DL, Satlin A. Antihypertensive efficacy and safety of the oral renin inhibitor aliskiren in patients with hypertension: A pooled analysis [abstract]. Eur Heart J 2006; 27: 299.
23. Pool JL, Schmieder RE, Azizi M, Aldigier JC, Januszewicz A, Zidek W, Chiang Y, Satlin A. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007; 20: 11-20.
24. Verdecchia P, Calvo C, Möckel V, Keeling L, Satlin A. Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Blood Press 2007; 16: 381-391.